Faslodex CHMP positive opinion in 1L breast cancer
23 June 2017 12:45 BST FASLODEX (FULVESTRANT) RECEIVES POSITIVE CHMP OPINION FOR USE IN 1st-LINE HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER CHMP positive recommendation is based on Phase III data demonstratinga 20% reduction in risk of disease worsening or death over anastrozole AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorisation of Faslodex (fulvestrant) for the treatment of hormone receptor-positive (HR+), locally-advanced